Comparative Effectiveness Study of Drug-Eluting and Bare-Metal Peripheral Artery Stents in Endovascular Femoropopliteal Artery Revascularization

被引:0
|
作者
Jeon-Slaughter, Haekyung [1 ,2 ]
Khalili, Houman [1 ,2 ]
Tsai, Shirling [1 ,2 ]
Armstrong, Ehrin J. [3 ,4 ]
Shammas, Nicolas W. [5 ]
Jawaid, Omar [3 ,4 ]
Lu, Hua [1 ,2 ]
Addo, Tayo [1 ]
Gigliotti, Osvaldo [6 ]
Abu-Fadel, Mazen [7 ]
Banerjee, Subhash [1 ,2 ]
机构
[1] Univ Texas Southwestern Med Ctr Dallas, 4500 S Lancaster Rd 111a, Dallas, TX 75216 USA
[2] Dallas VA Med Ctr, Dallas, TX USA
[3] Eastern Colorado VA Med Ctr, Denver, CO USA
[4] Univ Colorado, Denver, CO 80202 USA
[5] Midwest Cardiovasc Res Fdn, Davenport, IA USA
[6] New Braunfels Cardiol, New Braunfels, TX USA
[7] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA
来源
JOURNAL OF INVASIVE CARDIOLOGY | 2018年 / 30卷 / 10期
关键词
endovascular revascularization; drug-eluting stent; peripheral artery disease; propensity score matching; stent; Zilver PTX; ZILVER PTX; PROPENSITY SCORE; DISEASE; RESTENOSIS;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. Paclitaxel drug-eluting stents [DES] have been shown to improve primary patency of femoropopliteal lesions compared to plain balloon angioplasty with provisional bare-metal stents [BMS] in randomized controlled studies. However, data are lacking on patency outcomes of real-world DES use relative to BMS use. This study compared clinically driven target-lesion revascularization [TLR], target-vessel revascularization [TVR], and target-limb revascularization outcomes at 1 year between DES and BMS treatments in a real-world setting. Methods. The study identified 174 DES (Zilver PTX; Cook Medical) and 784 BMS femoropopliteal interventions from the available 969 Excellence in Peripheral Artery Disease [XLPAD] registry patients between October 2013 and December 2016. We analyzed both unmatched (174 DES and 784 BMS) and propensity score [PS]-matched datasets [174 for each]. Results. This study found that patients who underwent DES femoropopliteal endovascular revascularization had significantly lower TLR rates in both unmatched (hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.35-0.91; P=.02] and matched data [HR. 0.50 95% CI, 0.27-0.91; P=.02]. The DES group had a 43% lower TVR risk than the BMS group in the PS matched cohort [HR, 0.57; 95% CI, 0.33-0.98; P=.04). Mortality rate in the DES group [5%] was significantly higher than the BMS group in both unmatched [2%; P=.04] and matched groups [1%; P=.046] at 1 year. Conclusions. Patients treated with DES had higher lesion and vessel patency than BMS after adjusting for confounding, which included complexity of lesion characteristics and operators' clinical decision-making regarding selection of treatment modalities, in femoropopliteal endovascular interventions in a real-world registry.
引用
收藏
页码:373 / 379
页数:7
相关论文
共 50 条
  • [31] Analysis of the Cost-Effectiveness of Drug-Eluting and Bare-Metal Stents in Coronary Disease
    Ferreira, Esmeralci
    Araujo, Denizar Vianna
    Pereira Azevedo, Vitor Manuel
    Rodrigues, Cyro Vargues
    Ferreira, Alcides, Jr.
    Junqueira, Camillo de Lellis
    de Castro Aminos, Jose Geraldo
    Farias, Mara Lucia
    Neto, Antonio Farias
    de Albuquerque, Denilson Campos
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2010, 94 (03) : 306 - 312
  • [32] Target Lesion Revascularization after Bare-Metal or Drug-Eluting Stents: Clinical Presentations and Outcomes
    Hayes, Kevin R.
    Applegate, Robert J.
    Sacrinty, Matthew T.
    Kutcher, Michael A.
    Gandhi, Sanjay K.
    Santos, Renato M.
    Little, William C.
    JOURNAL OF INVASIVE CARDIOLOGY, 2010, 22 (06): : 266 - 270
  • [33] Drug-eluting stents versus bare-metal stents for acute coronary syndrome
    Feinberg, Joshua
    Nielsen, Emil Eik
    Greenhalgh, Janette
    Hounsome, Juliet
    Sethi, Naqash J.
    Safi, Sanam
    Gluud, Christian
    Jakobsen, Janus C.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (08):
  • [34] Comparison in survival outcomes between drug-eluting stents and bare-metal stents
    Omerovic, E.
    EUROPEAN HEART JOURNAL, 2012, 33 : 554 - 554
  • [35] Treatment of Hepatic Artery Stenosis in Liver Transplant Patients Using Drug-Eluting versus Bare-Metal Stents
    Naidu, Sailendra
    Alzubaidi, Sadeer
    Knuttinen, Grace
    Patel, Indravadan
    Fleck, Andrew
    Sweeney, John
    Aqel, Bashar
    Larsen, Brandon
    Buras, Matthew
    Golafshar, Michael
    Oklu, Rahmi
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (03) : 1 - 11
  • [36] Incidence and predictors of clinically driven target lesion revascularization from bare-metal stents to drug-eluting stents
    Park, Seung-Jung
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2007, 70 (02) : 184 - 184
  • [37] Outcomes in the Era of Bare-Metal Stents vs the Era of Drug-Eluting Stents
    Beri, Abhimanyu
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 301 (01): : 33 - 33
  • [38] Outcomes of Diabetics Receiving Bare-Metal Stents Versus Drug-Eluting Stents
    Ramanath, Vijay S.
    Brown, Jeremiah R.
    Malenka, David J.
    DeVries, James T.
    Sidhu, Mandeep S.
    Robb, John F.
    Jayne, John E.
    Hettleman, Bruce D.
    Friedman, Bruce J.
    Niles, Nathaniel W., II
    Kaplan, Aaron V.
    Thompson, Craig A.
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2010, 76 (04) : 473 - 481
  • [39] Comparison of drug-eluting and bare metal stents for extracranial vertebral artery stenting
    Maciejewski, Damian R.
    Pieniazek, Piotr
    Tekieli, Lukasz
    Paluszek, Piotr
    Przewlocki, Tadeusz
    Tomaszewski, Tomasz
    Machnik, Roman
    Trystula, Mariusz
    Legutko, Jacek
    Kablak-Ziembicka, Anna
    POSTEPY W KARDIOLOGII INTERWENCYJNEJ, 2019, 15 (03): : 328 - 337
  • [40] Lack of Clinical Benefit of Drug-Eluting Compared to Bare-Metal Stents for Treatment of Transplant Coronary Artery Disease: Why We Do Not Need Drug-Eluting Stents?
    Fernandez-Pereira, Carlos
    Mieres, Juan
    Rodriguez, Alfredo E.
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2013, 82 (02) : 237 - 237